Acutaas Chemicals Limited (NSE:ACUTAAS)
India · Delayed Price · Currency is INR | Market Cap | 247.16B +160.0% |
| Revenue (ttm) | 13.39B +33.0% |
| Net Income | 3.56B +124.5% |
| EPS | 43.37 +118.9% |
| Shares Out | 81.87M |
| PE Ratio | 69.61 |
| Forward PE | 56.60 |
| Dividend | 2.50 (0.08%) |
| Ex-Dividend Date | n/a |
| Volume | 305,940 |
| Open | 3,176.70 |
| Previous Close | 3,132.50 |
| Day's Range | 3,005.30 - 3,188.10 |
| 52-Week Range | 1,059.00 - 3,188.10 |
| Beta | -0.10 |
| Analysts | Buy |
| Price Target | 2,486.33 (-17.64%) |
| Earnings Date | Jul 30, 2026 |
About Acutaas Chemicals
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist... [Read more]
Financial Performance
In fiscal year 2026, Acutaas Chemicals's revenue was 13.39 billion, an increase of 33.02% compared to the previous year's 10.07 billion. Earnings were 3.56 billion, an increase of 124.46%.
Financial StatementsNews
Acutaas Chemicals Slides: Corporate presentation
Acutaas Chemicals has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Acutaas Chemicals Transcript: Q4 25/26
Record FY26 revenue and PAT driven by strong growth in pharma intermediates, specialty, and battery chemicals. FY27 guidance targets 25-28% revenue growth with stable margins, supported by robust order book and new product launches.
Acutaas Chemicals Quarterly report: Q4 2026
Acutaas Chemicals has published its Q4 2026 quarterly earnings report on April 30, 2026.
Acutaas Chemicals Slides: Q4 2026
Acutaas Chemicals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 30, 2026.
Acutaas Chemicals Transcript: Q3 25/26
Q3 FY 2026 saw revenue rise 43% year-over-year to INR 393.2 crore, with record-high margins and profit after tax exceeding INR 100 crore. Upgraded FY 2026 guidance projects 30% revenue growth and 32–35% EBITDA margin, driven by strong CDMO, battery, and semiconductor segments.
Acutaas Chemicals Quarterly report: Q3 2026
Acutaas Chemicals has published its Q3 2026 quarterly earnings report on January 28, 2026.
Acutaas Chemicals Slides: Q3 2026
Acutaas Chemicals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 28, 2026.
Acutaas Chemicals Transcript: Q2 25/26
Q2 FY26 saw 34% YOY revenue growth and significant margin expansion, led by pharma intermediates and CDMO. Battery chemicals and semiconductor JVs are set to drive future growth, with robust CapEx and strong cash reserves supporting expansion.
Acutaas Chemicals Quarterly report: Q2 2026
Acutaas Chemicals has published its Q2 2026 quarterly earnings report on October 17, 2025.
Acutaas Chemicals Slides: Q2 2026
Acutaas Chemicals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 17, 2025.
Acutaas Chemicals Transcript: Q1 25/26
Q1 FY 2026 revenue rose 17.3% YoY, led by pharma intermediates and strong margin expansion. Major CapEx in battery and semiconductor chemicals is underway, with new products and contracts set to drive growth. Management reaffirms 25% revenue growth guidance for FY 2026.
Acutaas Chemicals Quarterly report: Q1 2026
Acutaas Chemicals has published its Q1 2026 quarterly earnings report on July 30, 2025.
Acutaas Chemicals Slides: Q1 2026
Acutaas Chemicals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 30, 2025.